We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 50.23 | 0 | 00:00:00 |
From Nov 2023 to Dec 2023
14:01 EST--Bristol Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Shares of Bristol Myers Squibb fell after the U.S. Food and Drug Administration delayed approval for Abecma, a blood cancer treatment it developed with 2seventy Bio, to be used earlier in the treatment process. It is currently approved for use after four or more prior lines of therapy. Bristol Myers and 2seventy share all profit and losses for the drug. Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)
(END) Dow Jones Newswires
November 20, 2023 14:16 ET (19:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
